Ibrance 75 mg
Ibrance 75 mg is a medicine authorised by Swissmedic under authorisation number 66138. The authorisation holder is Pfizer AG. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 31 January 2017 and the authorisation is valid without a time limit. ATC code L01EF01 places the medicine in the group Antineoplastic agents.
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Ibrance 75 mg, Hartkapseln | A | 31 January 2017 |
| 2 | Ibrance 100 mg, Hartkapseln | A | 31 January 2017 |
| 3 | Ibrance 125 mg, Hartkapseln | A | 31 January 2017 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 21 | Kapsel(n) | L01EF01 | 07.16.1. | A |
| 2 | 21 | Kapsel(n) | L01EF01 | 07.16.1. | A |
| 3 | 21 | Kapsel(n) | L01EF01 | 07.16.1. | A |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Ibrance 75 mg authorised in Switzerland?
Yes. Ibrance 75 mg is authorised by Swissmedic under authorisation number 66138, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Ibrance 75 mg have?
Ibrance 75 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Ibrance 75 mg?
The authorisation holder is Pfizer AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.